As of Feb 21
| -0.02 / -0.67%|
The 7 analysts offering 12-month price forecasts for Cardiome Pharma Corp have a median target of 6.90, with a high estimate of 9.50 and a low estimate of 3.50. The median estimate represents a +131.54% increase from the last price of 2.98.
The current consensus among 8 polled investment analysts is to Buy stock in Cardiome Pharma Corp. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.